(INSM) Insmed - NASDAQ
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 20.765m USD | Total Return: -3.1% in 12m
Avg Turnover: 404M
Qual. Beats: 1
Rev. Trend: 91.1%
Qual. Beats: 0
Warnings
Share dilution 19.1% YoY
Interest Coverage Ratio -13.4 is critical
Altman Z'' -8.42 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
Insmed Incorporated is a biopharmaceutical company that develops and commercializes therapies for patients with serious and rare diseases across the United States, Europe, Japan, and other international markets. The companys lead commercial product is ARIKAYCE, used to treat refractory nontuberculous mycobacterial lung infections, which is also being evaluated in a Phase 3 trial for mycobacterium avium complex lung disease as part of a combination antibacterial regimen.
Insmeds pipeline includes brensocatib, an oral DPP1 inhibitor in Phase 3 development for bronchiectasis and Phase 2 trials for chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. The company is also advancing treprostinil palmitil inhalation powder, in Phase 3 for pulmonary hypertension associated with interstitial lung disease, alongside earlier-stage gene therapy candidates, including INS1201 for Duchenne muscular dystrophy and INS1202 for amyotrophic lateral sclerosis, as well as a monoclonal antibody (INS1148) targeting stem cell factor for interstitial lung disease and asthma.
Insmed was founded in 1988 and is headquartered in Bridgewater, New Jersey, and operates within the biotechnology sub-industry of the healthcare sector. The companys business model reflects a typical rare disease biotech approach, combining a single approved product generating revenue with a pipeline concentrated in late-stage clinical development targeting indications with limited existing treatment options.
- ARIKAYCE sales growth drives refractory NTM lung infection revenue
- Brensocatib phase 3 bronchiectasis trial readout as key catalyst
- Treprostinil palmitil phase 3 results in PH-ILD patients
| Net Income: -1.18b TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.51 > 0.02 and ΔFCF/TA -0.43 > 1.0 |
| NWC/Revenue: 152.8% < 20% (prev 305.3%; Δ -152.6% < -1%) |
| CFO/TA -0.43 > 3% & CFO -895.7m > Net Income -1.18b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.47 > 1.5 & < 3 |
| Outstanding Shares: last quarter (215.5m) vs 12m ago 19.14% < -2% |
| Gross Margin: 81.56% > 18% (prev 76.49%; Δ 5.06% > 0.5%) |
| Asset Turnover: 42.26% > 50% (prev 21.14%; Δ 21.12% > 0%) |
| Interest Coverage Ratio: -13.37 > 6 (EBIT TTM -1.10b / Interest Expense TTM 82.3m) |
| A: 0.60 (Total Current Assets 1.61b - Total Current Liabilities 361.0m) / Total Assets 2.08b |
| B: -2.79 (Retained Earnings -5.80b / Total Assets 2.08b) |
| C: -0.57 (EBIT TTM -1.10b / Avg Total Assets 1.94b) |
| D: 0.51 (Book Value of Equity 704.9m / Total Liabilities 1.37b) |
| Altman-Z'' = -8.42 = D |
| DSRI: 1.74 (Receivables 178.6m/47.7m, Revenue 819.6m/381.0m) |
| GMI: 0.94 (GM 76.49% / 81.56%) |
| AQI: 1.01 (AQ_t 0.16 / AQ_t-1 0.16) |
| SGI: 2.15 (Revenue 819.6m / 381.0m) |
| TATA: -0.14 (NI -1.18b - CFO -895.7m) / TA 2.08b) |
| Beneish M = -1.66 (Cap -4..+1) = CCC |
As of June 24, 2026, the stock is trading at USD 102.15 with a total of 4,199,550 shares traded. Over the past week, the price has changed by +4.81%, over one month by -6.17%, over three months by -29.05% and over the past year by -3.10%.
Current recommended Stop Loss: 95.50 (which is 6.5% or 1.2 ATR below the current price).
Insmed has received a consensus analysts rating of 4.81. Therefore, it is recommended to buy INSM.
- StrongBuy: 17
- Buy: 4
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 197.1 | 93% |
P/E Forward = 16.3666
P/S = 25.3365
P/B = 29.4599
P/EG = 1.0916
Revenue TTM = 819.6m USD
EBIT TTM = -1.10b USD
EBITDA TTM = -1.08b USD
Long Term Debt = 542.2m USD (from longTermDebt, last quarter)
Short Term Debt = 14.4m USD (from shortTermDebt, last quarter)
Debt = 786.5m USD (from shortLongTermDebtTotal, last quarter) + Leases 38.1m
Net Debt = -437.0m USD (calculated: Debt 786.5m - CCE 1.22b)
Enterprise Value = 20.3b USD (20.8b + Debt 786.5m - CCE 1.22b)
Interest Coverage Ratio = -13.37 (Ebit TTM -1.10b / Interest Expense TTM 82.3m)
EV/FCF = -19.14x (Enterprise Value 20.3b / FCF TTM -1.06b)
FCF Yield = -5.23% (FCF TTM -1.06b / Enterprise Value 20.3b)
FCF Margin = -129.6% (FCF TTM -1.06b / Revenue TTM 819.6m)
Net Margin = -144.4% (Net Income TTM -1.18b / Revenue TTM 819.6m)
Gross Margin = 81.56% ((Revenue TTM 819.6m - Cost of Revenue TTM 151.2m) / Revenue TTM)
Gross Margin QoQ = 83.82% (prev 83.24%)
Tobins Q-Ratio = 9.79 (Enterprise Value 20.3b / Total Assets 2.08b)
Interest Expense / Debt = 10.46% (Interest Expense 82.3m / Debt 786.5m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -869.2m (EBIT -1.10b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.71 (Total Current Assets 1.61b / Total Current Liabilities 434.4m)
Debt / Equity = 1.12 (Debt 786.5m / totalStockholderEquity, last quarter 704.9m)
Debt / EBITDA = 0.40 (negative EBITDA) (Net Debt -437.0m / EBITDA -1.08b)
Debt / FCF = 0.41 (negative FCF - burning cash) (Net Debt -437.0m / FCF TTM -1.06b)
Total Stockholder Equity = 909.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -61.04% (Net Income -1.18b / Total Assets 2.08b)
RoE = -130.1% (Net Income TTM -1.18b / Total Stockholder Equity 909.8m)
RoCE = -75.78% (EBIT -1.10b / Capital Employed (Equity 909.8m + L.T.Debt 542.2m))
RoIC = -51.48% (negative operating profit) (NOPAT -869.2m / Invested Capital 1.69b)
WACC = 7.62% (E(20.8b)/V(21.6b) * Re(7.60%) + D(786.5m)/V(21.6b) * Rd(10.46%) * (1-Tc(0.21)))
Discount Rate = 7.60% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 19.32%
[DCF] Fair Price = unknown (Cash Flow -1.06b)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.91 | # QB: 1
Revenue Correlation: 91.13 | Revenue CAGR: 38.91% | SUE: 0.56 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.74 | Chg30d=+4.89% | Revisions=-20% | Analysts=14
EPS next Quarter (2026-09-30): EPS=-0.62 | Chg30d=-3.14% | Revisions=-33% | Analysts=14
EPS current Year (2026-12-31): EPS=-2.71 | Chg30d=+2.08% | Revisions=-29% | GrowthEPS=+57.8% | GrowthRev=+178.3%
EPS next Year (2027-12-31): EPS=0.25 | Chg30d=-31.12% | Revisions=-53% | GrowthEPS=+109.4% | GrowthRev=+62.3%
[Analyst] Revisions Ratio: -53%